Dextran 1 Lipid Membrane Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preserving erythrocytes and thrombocytes are limited by short storage stability, leading to reduced efficacy and potential harm from stored blood products, while micelle and vesicle structures used for mRNA vaccines face challenges in maintaining stability during storage and transport.
Innovation Solution
The use of Dextran 1 as a lipid membrane stabilizing agent in preservation solutions for erythrocytes, thrombocytes, and micelles/vesicles, which provides safe and effective preservation at temperatures above 0°C, preventing ice crystal formation and oxidative damage, and extending storage life without causing anaphylactic reactions or bleeding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If larger Dextran molecules (40, 60, 70 kDa) are used for preservation, then membrane stabilization and prevention of haemolysis are achieved, but bleeding risk and anaphylactic reactions increase
Solution Approach 1:
The invention segments the dextran molecule by using smaller molecular weight dextran (1-10 kDa) instead of larger molecules (40-70 kDa). This segmentation reduces the molecular size to below the threshold that causes thrombocyte binding and clotting factor interference, thereby eliminating bleeding risk while retaining membrane stabilization properties.
Solution Approach 2:
The invention introduces a molecular weight threshold (1-10 kDa) as an intermediary parameter that mediates between the need for membrane stabilization and the risk of adverse reactions. This intermediate molecular size range provides the optimal balance: large enough to stabilize membranes effectively but small enough to avoid binding to thrombocytes and clotting factors.
2Duration of action of stationary object
If erythrocytes are stored for extended periods, then more blood products are available for transfusion, but storage lesions occur and efficacy decreases
Solution Approach 1:
The invention applies preliminary protection by adding small dextran to the preservation solution before storage begins. This pre-treatment stabilizes the erythrocyte membranes in advance, preventing the formation of storage lesions that would otherwise occur during extended storage, thereby maintaining efficacy throughout the storage period.
Solution Approach 2:
The invention changes the molecular weight parameter of the dextran used in preservation solutions from the conventional 40-70 kDa to 1-10 kDa. This parameter change fundamentally alters the interaction with erythrocyte membranes, providing continuous stabilization that prevents storage lesions and maintains ATP and 2,3-DPG levels, thereby preserving efficacy during extended storage.
3Duration of action of stationary object
If micelles or vesicles are frozen for preservation, then storage stability is improved, but ice crystal formation damages the lipid layer structure
Solution Approach 1:
The invention introduces small dextran as a molecular intermediary that inserts itself between water molecules and the lipid layer. This intermediary forms a protective barrier that prevents water from freezing into damaging ice crystals while allowing the lipid layer to remain flexible and intact during frozen storage.
Solution Approach 2:
The invention uses small dextran to form a flexible protective film around micelles and vesicles. This thin film of dextran acts as a molecular shield that maintains the structural integrity of the lipid layer during freezing and thawing cycles, preventing ice crystal penetration and mechanical damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dextran 1 significantly improves the storage stability of erythrocytes and thrombocytes, reducing haemolysis and oxidative damage, and enhances the integrity of micelles/vesicles, making blood products safer and more accessible, and extends the shelf-life of mRNA vaccine carriers.
Implementation Method 1
provides safe and effective preservation at temperatures above 0°C, preventing ice crystal formation
Implementation Method 2
reducing haemolysis and oxidative damage
Data Source
AI summary
The present invention relates to the use of Dextran 1 for the preservation of lipid layers, wherein the lipid layers are present in cells, micelles, or vesicles and wherein the cells, micelles, or vesicles are suspended in a solution, as well as a preservation solution for erythrocytes, a collection bag suitable for collecting blood, erythrocyte and/or thrombocyte, and a method of preserving lipid layers. The present invention relates to the use of Dextran 1 as a safe and effective lipid layer/membrane stabilizing agent.